Association For Molecular Pathology et al v. United States Patent and Trademark Office et al

Filing 188

FILING ERROR - DEFICIENT DOCKET ENTRY - DECLARATION of Laura P. Masurovsky in Support re: 186 MOTION to File Amicus Brief. Document filed by Genetic Alliance. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Masurovsky, Laura) Modified on 12/31/2009 (db).

Download PDF
Association For Molecular Pathology et al v. United States Patent and Trademark Office et al Doc. 188 Att. 1 Exhibit 1 Tech Transfer :: News & Events :: Success Stories Page 1 of 1 Printed from: Home (../../index.php) > News & Events (../news/index.php) > Success Stories (index.php) > Story Details Diagnostics for Cystic Fibrosis Cystic fibrosis is a debilitating hereditary disease that usually strikes its victims in early childhood. During the late 1980s, UM physician-geneticist Francis Collins, who currently directs the National Human Genome Research Institute, and Dr. Lap-Chee Tsui of Toronto's Hospital for Sick Children began a joint research project in hopes of devising a method for diagnosing and eventually treating the disorder. Within two years, the researchers successfully cloned and sequenced a gene encoding a protein known as the Cystic Fibrosis Transmembrane Regulator (CFTR). They then went on to discover that a mutant form of the CFTR gene, known as Delta 508, was the most common mutation causing the disease and was present in 90 percent of cystic fibrosis patients. Following that discovery, the University of Michigan and the Hospital for Sick Children (HSC) filed a joint patent application for the gene and the protein derived from it They also created an arrangement whereby the University of Michigan would oversee licensing activities in the U.S., the Hospital for Sick Children would take responsibility for all other licensees, and the two institutions would share royalties from these licenses. Through the efforts of UM Tech Transfer and the Hospital for Sick Children, non-exclusive licenses have been granted to companies throughout North America and Europe. The decision to license non-exclusively has encouraged competition among diagnostic laboratories and enabled the test to be widely available at an affordable cost. While one firm is currently involved in clinical trials with a potential gene therapy product to treat affected individuals, the vast majority--14 thus far-are either performing in-house testing for individuals who wish to know their CF carrier status and/or for newborns if requested, or are developing standardized test kits that will eventually be sold to service laboratories. Copyright 2009 University of Michigan 12/29/2009

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?